First-Line Osimertinib Beneficial in Advanced NSCLC.

Osimertinib is more effective as first-line therapy than other EGFR inhibitors for patients with advanced EGFR-mutated non-small cell lung cancer-notably Asians, who have a higher incidence of the disease compared with Western populations. The conclusion is based on data from a subgroup analysis of the phase III FLAURA trial.